drugset
drugset / Trial / NCT00960752

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

NCT00960752 ↗

Phase 2 Completed 47 enrolled M.D. Anderson Cancer Center
RandomizedFactorialOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.

Timeline

Start
2010-05-20
Primary completion
2020-07-20
Completion
2020-07-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator MELANOMA-ASSOCIATED ANTIGEN 3 Protein / enzyme biologic 1 ml Intrathecal
Comparator Resiquimod Small molecule — Topical
Comparator gp100 antigen Peptide 1 ml Intramuscular

Indications

melanoma